In The News

Keep updated with news and technological advancements from Pure Protein.

Featured News Articles


Emergent Technologies, Inc. announced today that it has hired seasoned business development professional and immunology expert Gregory Frank, Ph.D. as President of Pure Protein, LLC, a leading developer of soluble HLA protein reagents for use in therapeutic and diagnostic applications; and Pure MHC, LLC, developer of a proprietary technology used to discover novel targets to treat infectious disease and cancer.


Pure MHC, LLC, a provider of MHC-based diagnostics and therapeutics, and Catalent Pharma Solutions, the global leader in drug development solutions and advanced delivery technologies for pharmaceutical, biologic and consumer health products, today announced the signing of a product development agreement.


Pure Protein, L.L.C. (PURE) has announced the company will deliver twelve oral and print poster presentations at the Annual Meeting of the American Society of Histocompatibility and Immunogenetics (ASHI) in Puerto Rico, October 8th through October 12th.


Our news Archives


Phase II Grant to develop a Donor Specific Antibody (DSA) diagnostic microassay with greater specificity and accuracy for acute and chronic antibody mediated rejection (AMR) of organ transplants

Dr. Mayer will lead PTS's clinical research strategies and support ongoing business development.

ImmunoCellular Therapeutics Establishes Agreement with Pure MHC for Novel Quality Control Assay for ICT-107 Phase 3 Registrational Trial

PureMHC and PhosImmune Working Together On Immunotherapies for Cancer

The grant will support the development of a multi-analyte assay device to detect the adverse immunological response against either donor or recipient-derived HLA that often occurs in transplant patients.